Use of octreotide in the treatment of mesenteric angina

American Journal of Gastroenterology

Volumn 92, Issue 7, 1997, Pages 1222-1223

  Anderson, Simon H C ^a   Dalton, Harry R ^b  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; METHYLDOPA; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CHRONIC KIDNEY FAILURE; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; MALE; MESENTERY DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

HUMANS; ISCHEMIA; MALE; MESENTERY; MIDDLE AGED; OCTREOTIDE; SPLANCHNIC CIRCULATION; VASODILATOR AGENTS;

EID: 0030795920     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hollier LH, Bernatz PE, Pairolero PC, et al. Surgical management of chronic intestinal ischemia - A reappraisal. Surgery 1981;90:940-3.
2. Seemann WR, Kujat C, Urbanyi B, et al. Adenosine and diltiazem: New therapeutic aspects in the treatment of mesenteric insufficiency. Vasa 1984;13:65-71 (in German).
3. Bradbury AW, Brittenden J, McBride K, et al. Mesenteric ischaemia: A multidisciplinary approach. Br J Surg 1995;82:1446-59.
4. Pofahl WE, Arden WA, Beihn LD, et al. Small intestinal microcirculatory effects of octreotide. J Surg Res 1994;56:345-50.
5. Burroughs AK, McCormick PA. Somatostatin and octreotide in gastroenterology. Aliment Pharmacol Ther 1991;5:331-41.
6. Morris JB, Guerrero NH, Furth EE, et al. Somatostatin attenuates ischemic intestinal injury. Am J Surg 1993;165:676-80.
7. Terenius L. Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors. Eur J Pharmacol 1976;38: 211-3.
8. Chrubasik J, Meynadier J, Blond S, et al. Somatostatin, a potent analgesic. Lancet 1984;2:1208-9.
9. Steadman K, Franks A. A woman with malignant bowel obstruction who did not want to die with tubes. Lancet 1996;347:944.
10. Chey WD, Beydoun A, Roberts DJ, et al. Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. Am J Physiol 1995;269:G821-6.
11. Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996;277:1359-65.
12. Dowling RH, Hussaini SH, Murphy GM, et al. Gallstones during octreotide therapy. Digestion 1993;54:107-20.
13. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide. Br J Clin Pharmacol 1994;38:213-9.